MX2012007410A - Compuestos antivirales novedosos. - Google Patents

Compuestos antivirales novedosos.

Info

Publication number
MX2012007410A
MX2012007410A MX2012007410A MX2012007410A MX2012007410A MX 2012007410 A MX2012007410 A MX 2012007410A MX 2012007410 A MX2012007410 A MX 2012007410A MX 2012007410 A MX2012007410 A MX 2012007410A MX 2012007410 A MX2012007410 A MX 2012007410A
Authority
MX
Mexico
Prior art keywords
compounds
relates
treatment
viral infections
antiviral activity
Prior art date
Application number
MX2012007410A
Other languages
English (en)
Inventor
Patrick Chaltin
Frauke Christ
Zeger Debyser
Marc De Maeyer
Arnaud Marchand
Gunter Carlens
Damien Marchand
Arnout Voet
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0922520A external-priority patent/GB0922520D0/en
Priority claimed from GBGB1001204.5A external-priority patent/GB201001204D0/en
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of MX2012007410A publication Critical patent/MX2012007410A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

La presente invención se refiere a compuestos de la fórmula (A) como se definen en la presente que tienen actividad antiviral, de modo más específico propiedades inhibidoras de replicación de VIH (Virus de Inmunodeficiencia Humano). La invención se refiere también a composiciones farmacéuticas que comprenden una cantidad efectiva de dichos compuestos como ingredientes activos. Esta invención se refiere además al uso de dichos compuestos como medicinas o en la elaboración de un medicamento útil para el tratamiento de animales que padecen de infecciones virales, en particular infección por VIH. Esta invención se refiere además a métodos para el tratamiento de infecciones virales en animales mediante la administración de una cantidad terapéutica de dichos compuestos, opcionalmente combinados con uno o más de otros fármacos que tienen actividad antiviral (Ver Formula).
MX2012007410A 2009-12-23 2010-12-20 Compuestos antivirales novedosos. MX2012007410A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0922520A GB0922520D0 (en) 2009-12-23 2009-12-23 Novel antiviral compounds
GBGB1001204.5A GB201001204D0 (en) 2010-01-26 2010-01-26 Novel antiviral compounds
PCT/EP2010/070306 WO2011076765A1 (en) 2009-12-23 2010-12-20 Novel antiviral compounds

Publications (1)

Publication Number Publication Date
MX2012007410A true MX2012007410A (es) 2012-07-17

Family

ID=44246874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007410A MX2012007410A (es) 2009-12-23 2010-12-20 Compuestos antivirales novedosos.

Country Status (13)

Country Link
US (1) US20120316161A1 (es)
EP (1) EP2516008B1 (es)
JP (1) JP2013515692A (es)
KR (1) KR101483834B1 (es)
CN (1) CN102770181B (es)
AU (1) AU2010334958B2 (es)
CA (1) CA2781780C (es)
ES (1) ES2475970T3 (es)
IL (1) IL219965A0 (es)
MX (1) MX2012007410A (es)
PT (1) PT2516008E (es)
SG (2) SG10201408512RA (es)
WO (1) WO2011076765A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CA2802308C (en) 2010-07-02 2018-08-28 Lianhong Xu Napht-2-ylacetic acid derivatives to treat aids
JP5806735B2 (ja) 2010-07-02 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ抗ウイルス化合物としての２−キノリニル−酢酸誘導体
US8633200B2 (en) * 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
BR112013011991A2 (pt) 2010-11-15 2016-08-30 Viiv Healthcare Uk Ltd composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
EP2511273B8 (en) 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
EP2794611B1 (en) * 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) * 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2719685A1 (en) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
US9580431B2 (en) * 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN105189510B (zh) 2013-03-13 2017-05-17 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
EP2970273B1 (en) 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP6268656B2 (ja) 2013-03-14 2018-01-31 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
WO2014159959A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
EP3152211A1 (en) 2014-02-12 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015123230A1 (en) 2014-02-12 2015-08-20 Bristol-Myers Squibb Company Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126743A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3116879A1 (en) 2014-02-18 2017-01-18 VIIV Healthcare UK (No.5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126765A1 (en) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3116880B1 (en) 2014-02-20 2018-03-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
JP6579549B2 (ja) 2014-05-16 2019-09-25 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
KR101692478B1 (ko) 2014-07-10 2017-01-05 계명대학교 산학협력단 Ｓｙ­０２９를 유효성분으로 함유하는 항바이러스 조성물
CA2987384A1 (en) 2015-05-29 2016-12-08 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
US20180170903A1 (en) 2015-07-06 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10221156B2 (en) 2015-07-08 2019-03-05 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
KR20180025916A (ko) 2015-07-09 2018-03-09 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체
CN107820492A (zh) 2015-07-09 2018-03-20 Viiv保健英国第五有限公司 作为人类免疫缺陷病毒复制抑制剂的吡啶‑3‑基乙酸衍生物
KR20180035910A (ko) 2015-08-07 2018-04-06 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
CN108026113A (zh) 2015-08-10 2018-05-11 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的咪唑并吡啶大环类化合物
AR105653A1 (es) 2015-08-11 2017-10-25 VIIV HEALTHCARE UK (Nº 5) LTD Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
JP2018522913A (ja) 2015-08-12 2018-08-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
CA2995087A1 (en) 2015-08-12 2017-02-16 John F. Kadow 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
BR112018003181A2 (pt) 2015-08-20 2018-09-25 Viiv Healthcare Uk No 5 Ltd composto, composição, e, método para tratar infecção por hiv
EP3455214A1 (en) 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2019515003A (ja) 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
US20200325127A1 (en) 2016-05-11 2020-10-15 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201835068A (zh) 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物
JP2020503352A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100191774B1 (ko) * 1991-04-22 1999-06-15 오스카 아끼히꼬 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7148237B2 (en) * 2001-03-01 2006-12-12 Shionogi & Co., Ltd. Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Ｈｉｖ阻害剤
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
NZ533413A (en) 2001-12-12 2006-09-29 Bristol Myers Squibb Co HIV integrase inhibitors
JP4578101B2 (ja) 2001-12-21 2010-11-10 テイボテク・フアーマシユーチカルズ・リミテツド 幅広いスペクトルのｈｉｖプロテアーゼ阻害剤である複素環置換フェニル含有スルホンアミド
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
PA8586801A1 (es) * 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
EP2220084B1 (en) * 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
PT2516008E (pt) 2014-07-16
CN102770181A (zh) 2012-11-07
AU2010334958B2 (en) 2015-02-05
AU2010334958A1 (en) 2012-06-07
CN102770181B (zh) 2015-08-12
EP2516008A1 (en) 2012-10-31
IL219965A0 (en) 2012-07-31
KR101483834B1 (ko) 2015-01-16
CA2781780A1 (en) 2011-06-30
WO2011076765A1 (en) 2011-06-30
SG10201408512RA (en) 2015-02-27
KR20120106869A (ko) 2012-09-26
EP2516008B1 (en) 2014-04-16
JP2013515692A (ja) 2013-05-09
US20120316161A1 (en) 2012-12-13
CA2781780C (en) 2015-02-17
ES2475970T3 (es) 2014-07-11
SG181423A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
MX2012007410A (es) Compuestos antivirales novedosos.
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
MX2020003055A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
SI2932970T1 (en) Antiviral therapy
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
EA200870183A1 (ru) Долговременное лечение вич-инфекции
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
SI2709613T1 (en) Procedures for the treatment of HCV
HRP20110800T1 (hr) UPORABA 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOKSO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILA ZA LIJEČENJE DIJABETESA, RAKA, AUTOIMUNIH POREMEĆAJA I ZARAZE HIV-om
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
BR112015010396A2 (pt) terapia de combinação
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
MX2008011020A (es) Compuestos de receptor sigma.
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
NZ700507A (en) Pyrimidine derivatives for the treatment of bacterial diseases
TH131128B (th) อนุพันธ์ไธอีโน [2,3-B] ไพริดีนเป็นตัวยับยั้งการเพิ่มจำนวนไวรัส (Theieno [2,3-B] Pyridine Derivatives as Viral Replication Inhibitors)
WO2010027189A3 (ko) 호모아이소플라베논 또는 이의 염의 신규한 용도
MD3446G2 (ro) Metodă de tratament al infecţiei HIV
TH131128A (th) อนุพันธ์ไธอีโน [2,3-B] ไพริดีนเป็นตัวยับยั้งการเพิ่มจำนวนไวรัส (Thieno [2,3-B] Pyridine Derivatives as Viral Replication Inhibitors)
MX2019015480A (es) Preparacion medicinal combinada para tratar infecciones virales.
EA201001301A1 (ru) Применение 1-метил-2-фенилтиометил-3-карбэтокси-4-диметиламинометил-5-окси-6-броминдола и его солей для профилактики и/или лечения инфекционных заболеваний животных вирусного генеза

Legal Events

Date Code Title Description
FG Grant or registration